TY - JOUR
T1 - Effects of intraperitoneal hyperthermic chemotherapy in ovarian cancer
AU - Ryu, Ki Sung
AU - Kim, Jae Hoon
AU - Ko, Hyun Sun
AU - Kim, Jin Woo
AU - Ahn, Woong Shick
AU - Park, Yong Gyu
AU - Kim, Seung Jo
AU - Lee, Joon Mo
PY - 2004/8
Y1 - 2004/8
N2 - Objectives. To evaluate the clinical effect of intraperitoneal hyperthermic chemotherapy (IPHC) in ovarian cancer patients. Patients and methods. We retrospectively reviewed 117 stages Ic-III ovarian cancer patients, who were diagnosed at the Gynecology Department of Kangnam St. Mary's Hospital between January 1994 and January 2000. Of these, 57 patients underwent cytoreductive surgery (conventional treatment) with IPHC and 60 patients (control group) underwent conventional treatment only. IPHC consisted of administering a mixture of 350 mg/m2 of carboplatin and 5,000,000 IU/m2 of interferon-α, and maintaining the intraperitoneal temperature at 43-44°C during surgery. Results. The overall 5-year survival rate was 58.6%; that of the IPHC group was 63.4% vs. 52.8% in the control group, with significantly higher survival in the IPHC group (P = 0.0078). Considering stage III ovarian cancer patients only (n = 74), the survival rate was 53.8% in the IPHC group (n = 35) and 33.3% in the control group (n = 39) and was significantly higher in the IPHC group (P = 0.0015). For stage III ovarian cancer patients whose tumor was reduced to less than 1 cm during a second procedure (n = 53), the 5-year survival rate was 65.6% in patients who underwent IPHC (n = 26) and 40.7% in the control patients (n = 27) (P = 0.0046). IPHC was an independent prognostic factor that was not affected by surgical staging, tumor size after second surgery, or patient age, according to a multivariate analysis (Hazard ratio = 0.496, P = 0.0176). Conclusion. Our study suggests that IPHC is a promising new treatment modality in ovarian cancer.
AB - Objectives. To evaluate the clinical effect of intraperitoneal hyperthermic chemotherapy (IPHC) in ovarian cancer patients. Patients and methods. We retrospectively reviewed 117 stages Ic-III ovarian cancer patients, who were diagnosed at the Gynecology Department of Kangnam St. Mary's Hospital between January 1994 and January 2000. Of these, 57 patients underwent cytoreductive surgery (conventional treatment) with IPHC and 60 patients (control group) underwent conventional treatment only. IPHC consisted of administering a mixture of 350 mg/m2 of carboplatin and 5,000,000 IU/m2 of interferon-α, and maintaining the intraperitoneal temperature at 43-44°C during surgery. Results. The overall 5-year survival rate was 58.6%; that of the IPHC group was 63.4% vs. 52.8% in the control group, with significantly higher survival in the IPHC group (P = 0.0078). Considering stage III ovarian cancer patients only (n = 74), the survival rate was 53.8% in the IPHC group (n = 35) and 33.3% in the control group (n = 39) and was significantly higher in the IPHC group (P = 0.0015). For stage III ovarian cancer patients whose tumor was reduced to less than 1 cm during a second procedure (n = 53), the 5-year survival rate was 65.6% in patients who underwent IPHC (n = 26) and 40.7% in the control patients (n = 27) (P = 0.0046). IPHC was an independent prognostic factor that was not affected by surgical staging, tumor size after second surgery, or patient age, according to a multivariate analysis (Hazard ratio = 0.496, P = 0.0176). Conclusion. Our study suggests that IPHC is a promising new treatment modality in ovarian cancer.
UR - http://www.scopus.com/inward/record.url?scp=3543129479&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=3543129479&partnerID=8YFLogxK
U2 - 10.1016/j.ygyno.2004.05.044
DO - 10.1016/j.ygyno.2004.05.044
M3 - Article
C2 - 15297169
AN - SCOPUS:3543129479
SN - 0090-8258
VL - 94
SP - 325
EP - 332
JO - Gynecologic Oncology
JF - Gynecologic Oncology
IS - 2
ER -
